z-logo
open-access-imgOpen Access
A review of the research progress in T-lymphocyte immunity and cervical cancer
Author(s) -
Lina Zhang,
Zhilei Mao,
Yiqing Lai,
Ting Wan,
Keliang Zhang,
Beibei Zhou
Publication year - 2020
Publication title -
translational cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.254
H-Index - 30
eISSN - 2219-6803
pISSN - 2218-676X
DOI - 10.21037/tcr.2020.01.33
Subject(s) - cervical cancer , immunity , medicine , immunology , immunotherapy , immune system , cancer , radiation therapy , evasion (ethics) , vaccination , antigen , t cell , cellular immunity , human papillomavirus , oncology
Cervical cancer develops as a result of T-cell immune evasion by human papillomavirus (HPV). T-cell immunity requires the participation of many factors, such as antigen-presenting cells (APCs), cytokines, co-stimulatory molecules, etc. HPV vaccines are promising treatments to prevent HPV infection and cervical cancer. This article mainly provides a summary of the number and function changes of T cells during HPV infection and cervical cancer development. Studies on t-cell immunotherapy, which is expected to become a new treatment for cervical cancer after surgery, radiotherapy, and chemotherapy, are also reviewed in this article.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom